T3D-959
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
1
Recruiting
0
Completed
2
Sites
5
Countries
1
Endpoints
21
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 21 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 6 of 21 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
3
1
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT02560753Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease | T3D-959 Alzheimer’s disease | mild-to-moderate AD | Ph 1/2 | Completed | 3 | May 2016 | 2 | results |
| NCT06964230A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects | T3D-959 Alzheimer’s disease | mild-to-moderate AD | Ph 2/3 | Not yet recruiting | 1 | Apr 2031 | - | |
| NCT04251182Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects | T3D-959 Alzheimer’s disease | mild-to-moderate AD | Ph 2 | Completed | 1 | Jan 2023 | - |
Showing 1-3 of 3 trials